Publication:

Omalizumab in chronic spontaneous urticaria

Background Chronic spontaneous urticaria is a common skin disorder affecting 0.5 to 1% of people in the general population. There are a variety of treatment options available without much successful outcome. Omalizumab is a novel treatment option which can be used in the treatment of chronic spontaneous urticaria. The aim of our study is to assess the efficacy of omalizumab in chronic spontaneous urticaria.

Methods A retrospective analysis of data of 10 patients with chronic spontaneous urticaria who were treated with three doses of omalizumab in our institution. Doses were given at monthly intervals for 3 months and they were followed for another 6 months. Response was assessed using urticaria activity score.

Results 70% of patients had well controlled urticaria with 3 doses of omalizumab by the end of 9 months.

Conclusions Omalizumab is a safe and effective treatment option in the management of chronic spontaneous urticaria.